Prostat Kanserli Hastalarda Bilateral Orkiektomi ve Flutamid Tedavisinin Karşılaştırılması

Year 1992, Volume: 45 Issue: 4, 777 - 784, 31.12.1992

Hamit Ersoy

Abstract

W, hormonal tedavi gerektiren 31 prostat kanseri hastasına bilateral orşiektomi uyguladı ve 15'ine steroid olmayan anti-androjen flutamid (750 mg/gün) tedavisi ekledi. Tek orşiektomi uygulanan grupta %-67 başarı oranı elde ederken; kombine tedavi alan grupta ilk yıl başarı oranı %92 oldu. Çiftçi grubunda %58 ve ikinci yılda ikinci grupta %8 oranında ilerleme görüldü. İki grup arasında istatistiksel olarak anlamlı bir fark olmasına rağmen, fhutamid eklendiğinde anti-androjen tedavisinin daha başarılı olduğunu gözlemledik. Prostat kanserinin heterojenliği ve anti-androjen tedaviye rağmen intraprostatik dihidrotestesteronun varlığı, başarı oranını zamanla azaltır ve nükslere neden olur:

Keywords

Brosiat kenseri , anti-androjen edna-Flutamid , bilateral orkiektomi

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

‘Bilateral Orchiectomi Versus Bilateral Orchiectomi : And Flutamid “ , In Prostate Cancer Patients

Abstract

“W performed bilateral orchiectomi to the-31 prostate cancer. patiérits requiring hormonal therapy and added non-steroidal anti-androgen flutamid (750 mg/day) therapy to the 15 of them. While we got
the %:-67 success rate in the only orchiectomi: performed group; ‘the
success rate was % 92 in the combined therapy receiving group for
the first year. Progression was observed ‘in’ % 58 in the farmer’ group
and % 8 in the latter for the second year. Despite there was fio statistically meaningful difference between: two groups, we observed:-that:
the anti-androgen therapy was more suctessfull' by adding fhutamid.
The heterogeneity of the prostat cancer and the presente ‘of intraprostatic dihydrotestesterone despite anti-androgen therapy decrease
the success rate by the time being and cause relaps:

Keywords

Prostate cancer , anti-androjen therapy , Flutamid

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Bruchovsky N Rennis PS Goldenberg SL: Mechanizm and effect of androgen withdrawal therapies. In H. Klosterhalfen (ed) : New Developments in Biosiciences 4, sayfa 5 Walter de Gruyter Berlin. 1988.
• 2, Cowley TH Brownsey BG Harper ME: The effect of ACTH on plasma testesterone and androstenedione concentrations in patients prostatic carcinoma. Acta Endocrinol Cophen. 81 ; 310, 1976.
• 3. Crawford ED Hisenberger MA McLeod DG : A controlled trial of Lauprolide with or without Flutamide in prostatic carcinoma. N. Eng. J. Med. 321 - 419, 1989. Sa
• 4.Geller J ; Rationale for blockage of adrenal as wall as testicular androgens in the treatment of advenced prostate cancer. Semin. Oncol. 12 (1) : 28, 1985,
• 5.Isaacs J Kyprianov N : Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urol. Res. 15 : 133, 1987. a
• 6. Iversen P Christensen MG Friis E: A Phase III Trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with carcinoma of the prostate : Response to serum testesterone and clinical response to subsequent estrogen therapy. Urology 17 : 49, 1981,
• 7.Klugo RC Farrah RN Cerny JC : Bilateral orchectomy for carcinoma of the prostate : Response to serum testosterone and clinical response to subsequent estrogen therapy. Urology 17: 49, 1981.
• 8.Labrie F Dupond A Belanger A : Antiandrogens and LHRH agoinst in the treatment of prostatic cancer. Medicine/Science 1/ : 435, 1985.
• 9.Labrie’ F Dupond A Belanger A : New approach in the treatment of prostate cancer : Complete instead of partial withdrawal of androgens. Prostate 4 : 579, 1983.
• 10.Labrie F Dupond A Cusan L Giguere M : Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previous] untreated patients with clinical stage D2 prostatecancer : Today's therapy of choice, J. Steroid Biochem 30: 107, 1988.
• 11.Labrie F Dupond A Belanger A Lachence R : Flutamide eleminates the risk of disease flare in prostatic cancer patients treated with a LHRH agonist. J. Urol. 138 : 804, 1987.
• 12.Resnick MI Grayhack JT : Treatment of stage IV carcinoma of the prostate Urol. Clin. N. Amer. 2 : 141, 1975.